APA (7th ed.) Citation

SA, O., C, J., H, G., E, V., G, M., A, A., . . . L, A. (2013). A highly potent and specific MET therapeutic protein antagonist with both ligand-dependent and ligand-independent activity. Molecular cancer therapeutics, 12(11), 2459. https://doi.org/10.1158/1535-7163.MCT-13-0318

Chicago Style (17th ed.) Citation

SA, Olwill, et al. "A Highly Potent and Specific MET Therapeutic Protein Antagonist with Both Ligand-dependent and Ligand-independent Activity." Molecular Cancer Therapeutics 12, no. 11 (2013): 2459. https://doi.org/10.1158/1535-7163.MCT-13-0318.

MLA (9th ed.) Citation

SA, Olwill, et al. "A Highly Potent and Specific MET Therapeutic Protein Antagonist with Both Ligand-dependent and Ligand-independent Activity." Molecular Cancer Therapeutics, vol. 12, no. 11, 2013, p. 2459, https://doi.org/10.1158/1535-7163.MCT-13-0318.